Current Report Filing (8-k)
June 02 2020 - 7:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of report
(Date of earliest event reported): June 2, 2020
Idera Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
001-31918
(Commission
File Number)
|
04-3072298
(I.R.S Employer
Identification No.)
|
505 Eagleview Blvd., Suite 212
Exton, Pennsylvania
(Address of Principal Executive
Offices)
|
|
19341
(Zip Code)
|
Registrant’s telephone number, including
area code: (484) 348-1600
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
IDRA
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 7.01
|
Regulation FD Disclosure.
|
On June 2, 2020, Idera Pharmaceuticals,
Inc. (the “Company,” “we,” “us,” and “our”) issued a press release announcing preliminary
data from the ILLUMINATE-206 trial for the treatment of micro-satellite stable colorectal cancer. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1.
The Company is furnishing the information
in this Item 7.01 and the related Exhibits 99.1 filed herewith to comply with Regulation FD. Such information shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings
under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation
language in such filings, except to the extent expressly set forth by specific reference in such a filing. This Item 7.01 will
not be deemed an admission as to the materiality of any information herein (including Exhibits 99.1) that is required to be disclosed
solely by Regulation FD.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IDERA PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Bryant D. Lim
|
|
|
Bryant D. Lim
|
|
|
Senior V.P., General Counsel
|
Dated: June 2, 2020
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2024 to May 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Idera Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Idera Pharmaceuticals, Inc. News Articles